A recent study demonstrates that the monoclonal antibody-based vaccine L9LS is safe for children aged 6 to 10 and significantly reduces the risk of malaria infection and clinical symptoms by 70% and 77%, respectively.
Researchers have identified a protein that evolved concurrently with the emergence of cellular compartments crucial for the multiplication of the toxoplasmosis pathogen.
Structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
1. Patients in the primaquine group reported a significant reduction in parasitemia risk at day 63 compared to those in the standard care group. 2. The majority of adverse events were mild-to-moderate with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: In areas where Plasmodium vivax and Plasmodium falciparum coexist, there exists an